The Department of Veterans Affairs is linking up with the Institute for Clinical and Economic Review to support use of ICER’s drug assessment reports in coverage and price negotiations with the pharmaceutical industry.

The reports include analyses of each therapy’s comparative clinical effectiveness, cost-effectiveness and potential budget impact. The VA will integrate public ICER reports into its formulary process to assess the value of drugs.

Under the agreement, ICER will work with VA staff to develop options for using value-based price benchmarks in negotiations with drugmakers.